Free Trial

AstraZeneca (AZN) Stock Price, News & Analysis

AstraZeneca logo
$69.60 -1.53 (-2.15%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$69.64 +0.04 (+0.06%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AstraZeneca Stock (NASDAQ:AZN)

Key Stats

Today's Range
$69.18
$71.16
50-Day Range
$66.23
$75.00
52-Week Range
$61.24
$87.68
Volume
6.77 million shs
Average Volume
5.25 million shs
Market Capitalization
$215.85 billion
P/E Ratio
27.95
Dividend Yield
2.96%
Price Target
$85.00
Consensus Rating
Moderate Buy

Company Overview

AstraZeneca Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

AZN MarketRank™: 

AstraZeneca scored higher than 47% of companies evaluated by MarketBeat, and ranked 1750th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    AstraZeneca has only been the subject of 1 research reports in the past 90 days.

  • Read more about AstraZeneca's stock forecast and price target.
  • Earnings Growth

    Earnings for AstraZeneca are expected to grow by 10.86% in the coming year, from $4.51 to $5.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 27.95, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 27.95, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

  • Price to Earnings Growth Ratio

    AstraZeneca has a PEG Ratio of 1.31. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AstraZeneca has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AstraZeneca's valuation and earnings.
  • Percentage of Shares Shorted

    0.24% of the float of AstraZeneca has been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently increased by 7.66%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    AstraZeneca pays a meaningful dividend of 2.90%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 82.73%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 41.20% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

  • Read more about AstraZeneca's dividend.
  • Percentage of Shares Shorted

    0.24% of the float of AstraZeneca has been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently increased by 7.66%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    AstraZeneca has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for AstraZeneca this week, compared to 26 articles on an average week.
  • Search Interest

    29 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 20.35% of the stock of AstraZeneca is held by institutions.

  • Read more about AstraZeneca's insider trading history.
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

Why AstraZeneca Stock Got Thumped on Thursday
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

AZN Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $65.52 at the beginning of the year. Since then, AZN stock has increased by 6.2% and is now trading at $69.60.

AstraZeneca PLC (NASDAQ:AZN) announced its earnings results on Tuesday, April, 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The business's revenue was up 7.2% compared to the same quarter last year.
Read the conference call transcript
.

AstraZeneca's stock split on the morning of Monday, July 27th 2015.The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

AstraZeneca subsidiaries include these companies: Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and more.

Top institutional investors of AstraZeneca include Park National Corp OH, Marotta Asset Management, Crumly & Associates Inc. and McLean Asset Management Corp.
View institutional ownership trends
.

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

Last Earnings
4/29/2025
Today
7/03/2025
Next Earnings (Estimated)
7/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AZN
Employees
94,300
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$85.00
High Stock Price Target
$95.00
Low Stock Price Target
$75.00
Potential Upside/Downside
+22.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
27.90
Forward P/E Ratio
15.40
P/E Growth
1.31
Net Income
$7.04 billion
Pretax Margin
16.90%

Debt

Sales & Book Value

Annual Sales
$54.98 billion
Cash Flow
$6.12 per share
Price / Cash Flow
11.35
Book Value
$13.18 per share
Price / Book
5.27

Miscellaneous

Outstanding Shares
3,101,316,000
Free Float
N/A
Market Cap
$215.43 billion
Optionable
Optionable
Beta
0.37

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:AZN) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners